Month: April 2016

GP’s and patients can be assured of a more accurate diagnosis with this product from Bedfont® Scientific.

This year, apprehensions have been rising about asthma after recent studies uncovered some horrific truths about asthma; Asthma UK found that over 120,000 asthma sufferers in the UK are at risk from wrongly prescribed medication, whilst NICE published their findings that 30% of people with asthma are suspected to have been misdiagnosed.

Asthma is an affliction that affects an incredible 334 million people worldwide and 5.4 million people alone in the UK.  This year World Asthma Day falls on 3rd May. This awareness day reoccurs every May in a bid to raise people’s awareness of this respiratory condition; how it can have a detrimental effect on your quality of life and in severe cases, result in death.

Bedfont Scientific based in Harrietsham, Kent, who are celebrating 40 years in business this year, manufacture a fractional exhaled nitric oxide (FeNO) breath analysis monitor that provides a quick, easy and non-invasive solution to the above-mentioned asthma concerns. 

Using FeNO measurements to monitor airway inflammation in asthma patients represents a significant advance in respiratory medicine. The NObreath FeNO test is a user-friendly way to assess patient adherence to treatment, enabling respiratory specialists to prescribe their patients the right levels of medication. Additionally, the NObreath FeNO test can help to differentiate between asthma and other respiratory conditions such as COPD, and asthma and COPD cross over syndrome (ACOS), resulting in fewer patients being misdiagnosed.

Natasha Smith, concerned mother of two, says,

“My eldest daughter was recently seen by the GP because we suspected she might have asthma. Reading the figures in the news recently published by Asthma UK and NICE has only increased my concerns about my daughter’s welfare. If a test like the NObreath’s was readily available at the doctors, it would put my mind at ease.”

Lois Penhaligan, Specialist Respiratory Physiologist, at the Lung Function Laboratory in Llandough, explains,

“This can be used with patients who have respiratory symptoms, particularly with an unexplained cough and we are looking for the possible cause. The FeNO breath test is used for an assessment of airway inflammation, for the assessment of the effectiveness of a treatment, for example, a bronchodilator and for the management of a disease, for example, asthma.”

A quick, easy and non-invasive breath test with the Gastrolyzer could help thousands of people suffering with IBS.

April is IBS awareness month and for the IBS Network’s 25th Anniversary show, they are highlighting IBS from the patient’s perspective.

IBS is a condition that affects 23% of people worldwide [1] and 10-20% of the UK’s population [2] alone, however, it’s thought that reported numbers are much higher due to many people not seeking medical advice. Often those diagnosed with IBS may, in fact, have a more simple-to-treat condition known as Small Intestinal Bacterial Overgrowth (SIBO). The condition produces symptoms similar to IBS and is caused by having too many bacteria in the gut.

Bedfont® Scientific, based in Harrietsham, Kent, manufacture the Gastrolyzer monitors that can help with the investigation of IBS through a simple breath test. By measuring the amount of hydrogen and methane in a patient’s breath that is caused by the breakdown of food in the gut, the Gastrolyzer investigates if a patient has IBS or if they instead have another gastrointestinal disorder, by detecting SIBO or any sugar-related food intolerances, including lactose intolerance.

 Jason Smith, Bedfont’s General Manager, comments,

“IBS Awareness Month is the perfect time to highlight the Gastrolyzer and how it can save both the patient’s and doctor’s time in diagnosing gastrointestinal disorders. 
Unlike more conventional methods which can take up to two weeks to diagnose, using the Gastrolyzer means patients will have an instant diagnosis so they do not have to prolong their discomfort, whilst health professionals can see up to 10 patients in one sitting with the protocol mode, saving valuable time. Additionally through breath analysis, because there is no need for a blood sample, people who have a fear of needles can now be diagnosed and treated at ease.”